Antimicrobial Resistance in Neisseria gonorrhoeae in the 21st Century: Past, Evolution, and Future

Magnus Unemo; William M. Shafer

doi:10.1128/cmr.00010-14

journal article Jul 01, 2014

Antimicrobial Resistance in Neisseria gonorrhoeae in the 21st Century: Past, Evolution, and Future

Magnus Unemo

William M. Shafer

Clinical Microbiology Reviews Vol. 27 No. 3 pp. 587-613 · American Society for Microbiology

View at Publisher Save 10.1128/cmr.00010-14

Abstract

SUMMARY

Neisseria gonorrhoeae
is evolving into a superbug with resistance to previously and currently recommended antimicrobials for treatment of gonorrhea, which is a major public health concern globally. Given the global nature of gonorrhea, the high rate of usage of antimicrobials, suboptimal control and monitoring of antimicrobial resistance (AMR) and treatment failures, slow update of treatment guidelines in most geographical settings, and the extraordinary capacity of the gonococci to develop and retain AMR, it is likely that the global problem of gonococcal AMR will worsen in the foreseeable future and that the severe complications of gonorrhea will emerge as a silent epidemic. By understanding the evolution, emergence, and spread of AMR in
N. gonorrhoeae
, including its molecular and phenotypic mechanisms, resistance to antimicrobials used clinically can be anticipated, future methods for genetic testing for AMR might permit region-specific and tailor-made antimicrobial therapy, and the design of novel antimicrobials to circumvent the resistance problems can be undertaken more rationally. This review focuses on the history and evolution of gonorrhea treatment regimens and emerging resistance to them, on genetic and phenotypic determinants of gonococcal resistance to previously and currently recommended antimicrobials, including biological costs or benefits; and on crucial actions and future advances necessary to detect and treat resistant gonococcal strains and, ultimately, retain gonorrhea as a treatable infection.

Topics

No keywords indexed for this article. Browse by subject →

References

348

[1]

World Health Organization (WHO). 2012. Global incidence and prevalence of selected curable sexually transmitted infections—2008. World Health Organization, Geneva, Switzerland.

[2]

10.1093/jac/dks162

[3]

10.1128/aac.00325-11

[4]

10.1128/aac.05760-11

[5]

10.2217/fmb.12.117

[6]

10.1056/nejmp1112456

[7]

10.1097/qco.0b013e32834e9a6a

[8]

10.1111/j.1749-6632.2011.06215.x

[9]

10.1093/jac/dks188

[10]

Groopman J . 1 October 2012. Sex and the superbug—the rise of drug-resistant gonorrhea. New Yorker 2012:26–30.

[11]

Centers for Disease Control and Prevention (CDC). 2012. Cephalosporin-resistant Neisseria gonorrhoeae public health response plan, p 1–43. CDC, Atlanta, GA.

[12]

European Centre for Disease Prevention and Control (ECDC). 2012. Response plan to control and manage the threat of multidrug-resistant gonorrhoea in Europe, p 1–23. ECDC, Stockholm, Sweden.

[13]

10.1136/sextrans-2012-050674

[14]

World Health Organization (WHO), Department of Reproductive Health and Research. 2012. Global action plan to control the spread and impact of antimicrobial resistance in Neisseria gonorrhoeae , p 1–36. WHO, Geneva, Switzerland.

[15]

Centers for Disease Control and Prevention (CDC). 2012. Update to CDC's sexually transmitted diseases treatment guidelines, 2010: oral cephalosporins no longer a recommended treatment for gonococcal infections. MMWR Morb. Mortal. Wkly. Rep. 61:590–594.

[16]

10.1258/ijsa.2011.011267

[17]

10.1177/0956462412472837

[18]

10.1016/s0140-6736(97)02190-9

[19]

10.1586/eri.09.63

[20]

Unemo M Ison C . 2013. Gonorrhoea, p 21–54. In Laboratory diagnosis of sexually transmitted infections, including human immunodeficiency virus. World Health Organization (WHO), Geneva, Switzerland.

[21]

10.1086/381895

[22]

10.1128/jcm.41.2.835-837.2003

[23]

10.1128/jcm.01217-11

[24]

10.2353/jmoldx.2006.050045

[25]

Smith DW Tapsall JW Lum G . 2005. Guidelines for the use and interpretation of nucleic acid detection tests for Neisseria gonorrhoeae in Australia: a position paper on behalf of the Public Health Laboratory Network. Commun. Dis. Intell. 29:358–365.

[26]

10.1007/978-1-61779-937-2_22

[27]

10.1371/journal.pmed.1001598

[28]

10.1136/sti.2010.044230

[29]

10.1006/mcpr.1998.0216

[30]

10.1093/jac/45.6.777

[31]

10.1128/jcm.02024-10

[32]

10.1128/aac.00385-09

[33]

10.1373/clinchem.2006.075309

[34]

10.1128/aac.00020-08

[35]

10.1111/j.1574-6968.2005.00053.x

[36]

10.1111/j.1574-6968.2008.01244.x

[37]

10.1128/aac.00309-10

[38]

10.1128/aac.01506-09

[39]

10.1093/cid/cir929

[40]

10.1128/aac.46.9.3020-3025.2002

[41]

10.1128/aac.43.6.1367

[42]

10.1128/aac.02093-13

[43]

10.1016/s0890-8508(03)00005-7

[44]

10.1007/s101560200025

[45]

10.1111/j.1600-0463.2006.apm_495.x

[46]

10.1016/j.ijantimicag.2013.02.026

[47]

10.1128/jcm.01909-06

[48]

10.1258/ijsa.2007.007206

[49]

10.1128/aac.01104-08

[50]

10.1128/jcm.01800-07

Showing 50 of 348 references

Cited By

1,008

Ceftriaxone-resistant Neisseria gonorrhoeae in Singapore: Eight years of sentinel surveillance

Ren Jie Tsai, Linus Cheng · 2026

International Journal of STD &...

Affinity of β-Lactam Antibiotics for Neisseria gonorrhoeae Penicillin-Binding Protein 2 Having Wild, Cefixime-Reduced-Susceptible, and Cephalosporin (Ceftriaxone)-Resistant penA Alleles

Yoshiki Hiyama, Soh Yamamoto · 2024

Microbial Drug Resistance

penA profile of Neisseria gonorrhoeae in Guangdong, China: Novel penA alleles are related to decreased susceptibility to ceftriaxone or cefixime

Yiwen Liao, Qinghui Xie · 2024

International Journal of Antimicrob...

Global patterns of syphilis, gonococcal infection, typhoid fever, paratyphoid fever, diphtheria, pertussis, tetanus, and leprosy from 1990 to 2021: findings from the Global Burden of Disease Study 2021

Weiye Chen, Yiming Chen · 2024

Infectious Diseases of Poverty

Doxycycline prophylaxis and meningococcal group B vaccine to prevent bacterial sexually transmitted infections in France (ANRS 174 DOXYVAC): a multicentre, open-label, randomised trial with a 2 × 2 factorial design

Jean-Michel Molina, Beatrice Bercot · 2024

The Lancet Infectious Diseases

Molecular Epidemiology of Penicillinase-Producing Neisseria gonorrhoeae Isolates and Their blaTEM-135 Gene Variant in Bangkok, Thailand, 2015–2017

Natakorn Nokchan, Perapon Nitayanon · 2023

Japanese Journal of Infectious Dise...

Multidrug-resistant Neisseria gonorrhoeae isolate SE690: mosaic penA-60.001 gene causing ceftriaxone resistance internationally has spread to the more antimicrobial-susceptible genomic lineage, Sweden, September 2022

Daniel Golparian, Nora Vestberg · 2023

Eurosurveillance

The oropharynx of men using HIV pre-exposure prophylaxis is enriched with antibiotic resistance genes: A cross-sectional observational metagenomic study

Christophe Van Dijck, Jolein Gyonne Elise Laumen · 2023

Journal of Infection

Important considerations regarding the widespread use of doxycycline chemoprophylaxis against sexually transmitted infections

Fabian Yuh Shiong Kong, Chris Kenyon · 2023

Journal of Antimicrobial Chemothera...

Antimicrobial use of patients with sexually transmitted infection symptoms prior to presentation at five health facilities in Southern Ghana

Naiki Attram, Helena Dela · 2023

Antimicrobial Resistance and Infect...

Emergence of a predominant sequence type ST7363 and the increasing trend of resistance to cefixime and ceftriaxone in Neisseria gonorrhoeae in Southern Taiwan, 2019–2021

Hsuan-Han Lin, Jia-Wen Li · 2023

Journal of Microbiology, Immunology...

High-level in vitro resistance to gentamicin acquired in a stepwise manner in Neisseria gonorrhoeae

Daniel Golparian, Susanne Jacobsson · 2023

Journal of Antimicrobial Chemothera...

Canary in the Coal Mine: How Resistance Surveillance in Commensals Could Help Curb the Spread of AMR in Pathogenic Neisseria

Maira Goytia, Crista B. Wadsworth · 2022

mBio

Prediction of antimicrobial minimal inhibitory concentrations for Neisseria gonorrhoeae using machine learning models

Muhammad Yasir, Asad Mustafa Karim · 2022

Saudi Journal of Biological Science...

Antimicrobial resistance prediction in Neisseria gonorrhoeae: current status and future prospects

Daniel Golparian, Magnus Unemo · 2022

Expert Review of Molecular Diagnost...

Potent In Vitro and Ex Vivo Anti-Gonococcal Activity of the RpoB Inhibitor Corallopyronin A

Jennifer L. Edwards, Jacqueline T. Balthazar · 2022

mSphere

Molecular characterization of decreased susceptibility to ceftriaxone and genotyping of Neisseria gonorrheae isolates in New Delhi, India

Neeraj Mahajan, Seema Sood · 2021

Diagnostic Microbiology and Infecti...

Prediction of ceftriaxone MIC inNeisseria gonorrhoeae usingDNA microarray technology and regression analysis

Boris Shaskolskiy, Ilya Kandinov · 2021

Journal of Antimicrobial Chemothera...

Molecular pathways to high-level azithromycin resistance in Neisseria gonorrhoeae

J G E Laumen, S S Manoharan-Basil · 2021

Journal of Antimicrobial Chemothera...

Gentamicin Susceptibility in Neisseria gonorrhoeae and Treatment Outcomes for Urogenital Gonorrhea After 25 Years of Sustained Gentamicin Use in Malawi

Mitch Matoga, Jane S. Chen · 2021

Sexually Transmitted Diseases

Metrics

1,008

Citations

348

References

Details

Published: Jul 01, 2014
Vol/Issue: 27(3)
Pages: 587-613
License: View

Authors

M

Magnus Unemo

WHO Collaborating Centre for Gonorrhoea and Other Sexually Transmitted Infections, National Reference Laboratory for Pathogenic Neisseria, Department of Laboratory Medicine, Microbiology, Örebro University Hospital, Örebro, Sweden

W

William M. Shafer

Department of Microbiology and Immunology, Emory University School of Medicine, Atlanta, Georgia, USA; Laboratories of Bacterial Pathogenesis, Veterans Affairs Medical Center, Decatur, Georgia, USA

Cite This Article

Magnus Unemo, William M. Shafer (2014). Antimicrobial Resistance in Neisseria gonorrhoeae in the 21st Century: Past, Evolution, and Future. Clinical Microbiology Reviews, 27(3), 587-613. https://doi.org/10.1128/cmr.00010-14

Antimicrobial Resistance in Neisseria gonorrhoeae in the 21st Century: Past, Evolution, and Future

You May Also Like